Vanguard Personalized Indexing Management LLC Has $3.28 Million Stock Holdings in Sanofi $SNY

Vanguard Personalized Indexing Management LLC decreased its stake in Sanofi (NASDAQ:SNY) by 26.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 69,453 shares of the company’s stock after selling 25,403 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Sanofi were worth $3,278,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Financial Consulate Inc. purchased a new stake in Sanofi during the third quarter valued at about $26,000. Ameritas Advisory Services LLC acquired a new stake in shares of Sanofi during the second quarter valued at approximately $28,000. First Horizon Corp acquired a new stake in shares of Sanofi during the third quarter valued at approximately $33,000. Salomon & Ludwin LLC lifted its position in shares of Sanofi by 1,046.3% in the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock valued at $39,000 after acquiring an additional 701 shares in the last quarter. Finally, Concord Wealth Partners boosted its stake in Sanofi by 510.3% in the 2nd quarter. Concord Wealth Partners now owns 885 shares of the company’s stock worth $43,000 after purchasing an additional 740 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $45.77 on Thursday. Sanofi has a one year low of $44.62 and a one year high of $60.12. The business’s 50-day moving average price is $48.24 and its two-hundred day moving average price is $48.72. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.30. The company has a market capitalization of $111.63 billion, a P/E ratio of 10.72, a price-to-earnings-growth ratio of 1.38 and a beta of 0.45.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Barclays downgraded shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. UBS Group reissued a “neutral” rating on shares of Sanofi in a research note on Friday, January 16th. HSBC restated a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.